Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)
Historic Times Interest Earned for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to -$928119.2.
- Inhibikase Therapeutics' Times Interest Earned fell 41696255.1% to -$928119.2 in Q1 2022 from the same period last year, while for Dec 2022 it was -$3.6 million, marking a year-over-year decrease of 48909522.26%. This contributed to the annual value of -$741.16 for FY2021, which is 67316.52% down from last year.
- According to the latest figures from Q1 2022, Inhibikase Therapeutics' Times Interest Earned is -$928119.2, which was down 41696255.1% from -$31908.0 recorded in Q4 2021.
- In the past 5 years, Inhibikase Therapeutics' Times Interest Earned ranged from a high of -$52.08 in Q2 2020 and a low of -$928119.2 during Q1 2022
- Its 3-year average for Times Interest Earned is -$109939.3, with a median of -$222.54 in 2021.
- Its Times Interest Earned has fluctuated over the past 5 years, first tumbled by 20598.01% in 2021, then crashed by 41696255.1% in 2022.
- Quarter analysis of 3 years shows Inhibikase Therapeutics' Times Interest Earned stood at -$168.21 in 2020, then tumbled by 18869.2% to -$31908.0 in 2021, then plummeted by 2808.74% to -$928119.2 in 2022.
- Its Times Interest Earned stands at -$928119.2 for Q1 2022, versus -$31908.0 for Q4 2021 and -$28478.0 for Q3 2021.